Biogen Idec first one fourth revenues boost 9 percent to $1.2 billion Biogen Idec Inc. , a worldwide biotechnology head in the discovery, advancement, commercialization and manufacturing of innovative therapies, announced its first one fourth 2011 results today.2 billion, a rise of 9 percent versus 2010. Global in-market product sales of TYSABRI in the 1st one fourth of 2011 were $349 million, a rise of 20 percent over the first quarter of 2010. The full total was made up of $170 million in U.S. Product sales and $179 million in sales to markets beyond your U.S. On a reported basis, calculated relative to accounting principles recognized in the U.S. , first quarter 2011 GAAP diluted EPS had been $1.20, a rise of 50 percent over the first one fourth of 2010. GAAP net gain due to Biogen Idec for the one fourth was $294 million, a rise of 35 percent over the first quarter of 2010.Node-positive breast tumor is a malignancy which has pass on beyond the breast to at least one lymph node. Study writer Dr. Miguel Martin, chairman of the Spanish Breast Cancer Analysis Group at the University Medical center in Madrid, says that the treatment offers an acceptable new therapeutic choice that increases the likelihood of a cure for node-positive breast cancer sufferers. The benefits are stated by him extend to all or any subsets of patients, including both pre-and post-menopausal women and the ones with hormonal or genetic risk factors for even more aggressive disease.